Ets proteins in biological control and cancer

The Ets family consists of a large number of evolutionarily conserved transcription factors, many of which have been implicated in tumor progression. Extensive studies on this family of proteins have focused so far mainly on the biochemical properties and cellular functions of individual factors. Since most of the Ets factors can bind to the core consensus DNA sequence GGAA/T in vitro, it has been a challenge to differentiate redundant from specific functions of various Ets proteins in vivo. Recent findings, however, suggest that such apparent redundancy may in fact be a central component of a network of differentially regulated specific Ets factors, resulting in distinct biological and pathological consequences. The programmed “Ets conversion” appears to play a critical role during tumor progression, especially in control of cellular changes during epithelial–mesenchymal transition and metastasis. Coordination of multiple Ets gene functions also mediates interactions between tumor and stromal cells. As such, these new insights may provide a novel view of the Ets gene family as well as a focal point for studying the complex biological control involved in tumor progression. © 2004 Wiley‐Liss, Inc.

[1]  D. Watson,et al.  Fli-1 Inhibits Collagen Type I Production in Dermal Fibroblasts via an Sp1-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[2]  D. Watson,et al.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. , 2003, The American journal of pathology.

[3]  A. Aplin,et al.  Integrin-Mediated Adhesion Regulates ERK Nuclear Translocation and Phosphorylation of Elk-1 , 2001, The Journal of cell biology.

[4]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[5]  P. Farnham,et al.  Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. , 2002, Methods.

[6]  Runzhao Li,et al.  EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes , 2000, Oncogene.

[7]  G M Rubin,et al.  A genetic screen for novel components of the Ras/Mitogen-activated protein kinase signaling pathway that interact with the yan gene of Drosophila identifies split ends, a new RNA recognition motif-containing protein. , 2000, Genetics.

[8]  F. Bartel,et al.  Mouse models in the study of the Ets family of transcription factors , 2000, Oncogene.

[9]  L. Trusolino,et al.  Interactions between growth factor receptors and adhesion molecules: breaking the rules. , 2003, Current opinion in cell biology.

[10]  V. Sementchenko,et al.  Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. , 2002, The Journal of biological chemistry.

[11]  D. Watson,et al.  Ets transcription factors cooperate with Sp1 to activate the human Tenascin-C promoter , 1999, Oncogene.

[12]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[13]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[14]  P. Jackers,et al.  Fli-1 Inhibits Collagen Type I Production in Dermal Fibroblasts via an Sp1-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[15]  V. Sementchenko,et al.  Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. , 2003, Cancer research.

[16]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[17]  V. Sementchenko,et al.  Ets1 Is an Effector of the Transforming Growth Factor β (TGF-β) Signaling Pathway and an Antagonist of the Profibrotic Effects of TGF-β* , 2002, The Journal of Biological Chemistry.

[18]  Till Acker,et al.  Cooperative Interaction of Hypoxia-inducible Factor-2α (HIF-2α) and Ets-1 in the Transcriptional Activation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1)* , 2003, The Journal of Biological Chemistry.

[19]  R Favier,et al.  Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. , 2000, Immunity.

[20]  Mina J Bissell,et al.  The organizing principle: microenvironmental influences in the normal and malignant breast. , 2002, Differentiation; research in biological diversity.

[21]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[22]  Runzhao Li,et al.  EAPII interacts with ETS1 and modulates its transcriptional function , 2003, Oncogene.

[23]  R. Janknecht,et al.  Acetylation-Mediated Transcriptional Activation of the ETS Protein ER81 by p300, P/CAF, and HER2/Neu , 2003, Molecular and Cellular Biology.

[24]  R. Muise-Helmericks,et al.  Coordinated functions of Akt/PKB and ETS1 in tubule formation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  D. Brigstock,et al.  Connective tissue growth factor: what's in a name? , 2000, Molecular genetics and metabolism.

[26]  N. Bhat,et al.  The ets gene family. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  Hiroshi Kawada,et al.  Defective Megakaryopoiesis and Abnormal Erythroid Development inFli-1 Gene-Targeted Mice , 2001, International journal of hematology.

[28]  Runzhao Li,et al.  Regulation of Ets function by protein–protein interactions , 2000, Oncogene.

[29]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[30]  G. Martin,et al.  FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations , 1994, Cell.

[31]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[32]  C. Glass,et al.  An Induced Ets Repressor Complex Regulates Growth Arrest during Terminal Macrophage Differentiation , 2002, Cell.

[33]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[34]  M. Mareel,et al.  Clinical, cellular, and molecular aspects of cancer invasion. , 2003, Physiological reviews.

[35]  Jürgen Dittmer,et al.  The Biology of the Ets1 Proto-Oncogene , 2003, Molecular Cancer.